424B5 1 ny20062007x6_424b5.htm 424B5

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-292565

PROSPECTUS SUPPLEMENT

To Prospectus, dated January 8, 2026

34,782,609 Shares

Anteris Technologies Global Corp.

Common Stock

We are offering 34,782,609 of shares of our common stock, par value $0.0001 per share (“Common Stock”), pursuant to this prospectus supplement and the accompanying prospectus. The public offering price for each share of Common Stock is $5.75.

Concurrently with this offering, pursuant to a stock purchase agreement dated January 20, 2026 (the “Stock Purchase Agreement”), we have agreed to sell to Covidien Group S.à r.l., a wholly-owned subsidiary of Medtronic plc (the “Investor”), 15,652,173 shares of Common Stock, at a price per share equal to the public offering price in this offering. The Private Placement is being conducted pursuant to the exemption provided under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and, as such, the securities offered thereby are not being registered pursuant to this prospectus supplement and accompanying prospectus. This offering is not conditioned on the closing of the Private Placement; however, the completion of the Private Placement is contingent on the completion of this offering. This prospectus supplement and the accompanying prospectus are not an offer to sell or a solicitation of an offer to buy any securities in connection with the Private Placement.

Our Common Stock is listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “AVR.” Our CHESS Depositary Interests over our Common Stock (“CDIs”) trade on the Australian Securities Exchange (the “ASX”) under the symbol “AVR.” On January 20, 2026, the closing price for our Common Stock on Nasdaq was $5.75 per share.

Investing in our Common Stock involves a high degree of risk. See the sections titled “Risk Factors” beginning on page S-8 of this prospectus supplement and in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of the factors you should carefully consider before buying our Common Stock.

(1)	See the section of this prospectus supplement titled “Underwriting” for additional disclosure regarding underwriting discounts, commissions and expenses.

We have granted the underwriters an option to purchase up to an additional 5,217,391 shares of Common Stock, exercisable within a 30-day period, at the public offering price, less underwriting discounts and commissions.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

The underwriters expect to deliver the securities to purchasers on or about January 22, 2026.

The date of this prospectus supplement is January 20, 2026.


ABOUT THIS PROSPECTUS SUPPLEMENT			S-ii
PROSPECTUS SUPPLEMENT SUMMARY			S-1
THE COMPANY			S-1
RECENT DEVELOPMENTS			S-4
THE OFFERING			S-6
RISK FACTORS			S-8
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND MARKET DATA			S-10
USE OF PROCEEDS			S-12
DILUTION			S-13
THE CONCURRENT PRIVATE PLACEMENT			S-15
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS			S-17
UNDERWRITING			S-21
LEGAL MATTERS			S-28
EXPERTS			S-28
LIMITATION ON INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S LIABILITY			S-28
WHERE YOU CAN FIND MORE INFORMATION			S-28
INCORPORATION BY REFERENCE			S-29


ABOUT THIS PROSPECTUS			ii
CONVENTIONS WHICH APPLY IN THIS PROSPECTUS			ii
WHERE YOU CAN FIND ADDITIONAL INFORMATION			ii
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE			iii
THE COMPANY			1
RISK FACTORS			4
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS			5
USE OF PROCEEDS			6
DESCRIPTION OF CAPITAL STOCK			7
DESCRIPTION OF DEPOSITARY SHARES			14
DESCRIPTION OF WARRANTS			16
DESCRIPTION OF SUBSCRIPTION RIGHTS			18
DESCRIPTION OF CONTINGENT VALUE RIGHTS			19
DESCRIPTION OF DEBT SECURITIES			20
DESCRIPTION OF PURCHASE CONTRACTS			27
DESCRIPTION OF UNITS			28
PLAN OF DISTRIBUTION			29
LEGAL MATTERS			31
EXPERTS			31
LIMITATION ON INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S LIABILITY			31


Public offering price per share of Common Stock		$5.75
Net tangible book value per share as of September 30, 2025	$0.09
Increase in net tangible book value per share attributable to the pro forma adjustments described above	$0.54
Pro forma net tangible book value per share as of September 30, 2025	$0.63
Increase in pro forma net tangible book value per share attributable to this offering and the Private Placement	$2.62
Pro forma as adjusted net tangible book value per share as of September 30, 2025, after giving effect to this offering and the Private Placement		$3.25
Dilution per share to investors purchasing shares of Common Stock in this offering.		$2.50


Underwriter			Number of Securities
Barclays Capital Inc.			13,304,348
Wells Fargo Securities, LLC			13,304,348
Cantor Fitzgerald & Co.			8,173,913
Total			34,782,609


	Per Share		Total
	Without Option to Purchase Additional Shares	With Option to Purchase Additional Shares	Without Option to Purchase Additional Shares	With Option to Purchase Additional Shares
Public offering price	$5.75000	$5.75000	$200,000,001.75	$230,000,000.00
Underwriting discounts and commissions paid by us	$0.29325	$0.29325	$10,200,000.09	$11,730,000.00
Proceeds to us, before expenses	$5.45675	$5.45675	$189,800,001.66	$218,270,000.00

Offering price

$200,000,001.75

Underwriting discounts and commissions⁽¹⁾

$10,200,000.09

Proceeds, before expenses, to us

$189,800,001.66

SEC Form 424B5 filed by Anteris Technologies Global Corp.